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Introduction
            Sustained chronic tachyarrhythmias often cause a deterioration of cardiac function known 
as tachycardia-induced cardiomyopathy or tachycardiomyopathy.1 It has been recognized that 
the   tachycardiomyopathy   occurs   in   experimental   models2  and   also   in   patients   with 
supraventricular or ventricular tachycarrhythmias.3-6 Generally, cardiac function will recover if 
drug or catheter ablation therapy is successfully performed. Phillips and Levine7  initially 
presented this concept in 1949 for the relationship between rapid atrial fibrillation and reversible 
left ventricular (LV) failure. However, it might be difficult to define its cause and effect 
relationship   when   cardiomyopathy   and   tachycardia   are   identified   simultaneously.   The 
reversibility of LV dysfunction may often be variable and the precise mechanisms of the 
pathophysiological features of this phenomenon should be elucidated. Although excellent and 
comprehensive review articles by Fenelon G, et al.8 and Shinbane JS et al 9 regarding these 
topics have already been published, I will firstly present a typical case and then review the basic 
and clinical characteristics of tachycardiomyopathy in this article.                                      
Case   Presentation10                                                                               
            A 13-year-old girl was admitted with a chief complaint of orthopnea. She had been born 
with the congenital anomalies of spina bifida and common cloacae. At birth, an artificial anal 
and urinal plasties had been performed. At the age of 11 her urinary and anal tracts had been 
surgically separated. After the operation she has been doing well, but at the age of 13, orthopnea 
and edema of the lower extremities was noticed. She was referred to pediatrics and diagnosed as 
having congestive heart failure with atrial tachycardia. Digitalis, verapamil, and a small dose of 
metoprolol were not effective in controlling her arrhythmia, so she was referred to our 
department for further evaluation and treatment.                                                                 
            Physical examination indicated a small build (body height 112cm, weight 26kg) with 
underdevelopment of the lower extremities. Chest X-ray revealed marked cardiomegaly with a 
cardio-thoracic ratio of 77 % (Fig. 1A). On echocardiography, the left ventricular ejection 
fraction (LVEF) and the diastolic dimension were 0.21 and 51 mm, respectively. Her ECG 
showed atrial tachycardia with a heart rate of 150 beats per minute (bpm) and an upright P wave 
configuration in the limb leads of II,III, and aVf (Fig. 1B).                                                
            At first we sought to perform an electrophysiological study, but the venous approach for 
catheterization was quite difficult since the development of her bilateral femoral vein had been 
hindered by the operation for her congenital genito-urinal abnormality. Furthermore, the patient 
and her family were reluctant to accept invasive examination  or  treatment.  Thereafter,  we 
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decided to prescribe pilsicainide at an initial dose of 25 mg, and within 2 hours her ectopic atrial 
tachycardia was converted to a sinus rhythm. It was maintained by a daily dose of 75 mg 
pilsicainide from that day onward. After 3 months, chest X-rays showed an improvement of the 
cardiothoracic ratio to 46% (Fig. 1C), while her sinus rhythm was maintained using the same 
prescription (Fig. 1D). On echocardiography, the LV EF improved to 0.62 and the diastolic 
dimension decreased to 37 mm. She has been well in the four years since, and repeated Holter 
recordings have indicated the successful maintenance of sinus rhythm. 
Figure 1
(A) Chest X-P on admission. Cardiothrocic ratio was 77%.
(B) ECG with ectopic atrial tachycardia (150 bpm). 
(C) Chest X-P after pilsicainide administration. CTR was 46%.
(D) ECG with sinus rhythm (60 bpm).
Definition and Classification  
             Coined   by   Gallagher   JJ11  ,   the   term   tachycardia-induced   cardiomyopathy   or 
tachycardiomyopathy refers to impairment in LV function secondary to chronic tachycardia, 
which is partially or completely reversible after normalization of heart rate and/or rhythm 
irregularity. Later, Brugada P and Andries E12  defined that a "tachycardiomyopathy" is an 
abnormality of systolic or diastolic function of the heart, or both, usually resulting in heart 
dilatation and ultimately in heart failure caused by a high and/or irregular ventricular rate. This 
high and/or irregular ventricular rate may result from any type of cardiac arrhythmia.  
            Fenelon et al8 further classified tachycardiomyopathy into two categories. They are "pure 
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type" and "impure type" tachycardiomyopathy. In the former, chronic tachycardia causes LV 
dysfunction in a normal heart and completely recovers after termination of the tachycardia. In 
the latter, such a condition occurs in patients with structural heart diseases, and the cardiac 
dysfunction may only recover incompletely after termination of the tachycardia. The incomplete 
recovery of LV function might be the result of long-term tachycardia inducing irreversible 
myocardial   injury.                                                                        
Mechanism of Tachycardiomyopathy                                                                       
            There is no definite answer to the precise mechanism of tachycardiomyopathy in the 
clinical setting.8,9 Several experimental studies have however been helpful in understanding the 
pathophysiology of tachycardiomyopathy.                                                                     
Basic   mechanisms                                                                        
            Tomita et al13 investigated three groups of pigs:1)rapid left atrial pacing for 3 weeks, 
2)with a 4-week recovery period, and a 3)sham-group. In their experimental models, a 
continuous pacing rate of more than 240 beats/min for 3 weeks provoked the decrease of cardiac 
output, dilatation of the left ventricle, reduced systolic function and diastolic dysfunction, such 
as increased LV end-diastolic pressure, as well as neurohumoral abnormalities similar to human 
dilated cardiomyopathy. They found that LV wall thickness was  reduced, but the ventricular 
mass itself did not change. After termination of the pacing, systolic function recovered ,but 
diastolic function remained abnormal. Thus, the severity of LV dysfunction was related to the 
duration   of   tachyarrhythmias.                                                                      
            In chronic-paced animal models, the response to beta-adrenergic stimulation is known to 
be blunted. This may also be related to a decrease in the density of the beta-adrenergic 
receptors.14,15  These   facts   are   often   confirmed   in   clinical   situations.   Catecholamine 
concentrations in patients with heart failure are increased at rest and during low-level exercises, 
and attenuated during high-level exercises.16  Such inappropriate adrenergic responses may 
facilitate the development of tachycardiomyopathy and therefore, the efficacy of adequate beta-
blocker therapy may be expected in treating tachycardiomyopathy.17 Actually, beta-blockers had 
favorable effects in patients with dilated cardiomyopathy.18,19 Other neurohumoral activation 
has also been noted with a marked elevation of plasma natriuretic peptides, rennin activity and 
aldosterone   levels.20                                                                               
            Regarding other cellular functions, chronic SVT induced cardiomyopathy in swine was 
associated with decreased Na-K ATPase activity and glycoside receptor density and affinity.21,22 
Spinale et al reported that the contractile function in isolated myocytes is decreased due to the 
blunted response to any extracellular calcium overloads.23 According to He JQ et al24, cellular 
remodeling in heart failure results in the decreased density of T-tubules and L-type Ca2+ 
channels, which contribute to abnormal EC coupling. It may contribute to the reduction of 
contractility in tachycardia-induced cardiomyopathy. Furthermore, Williams R et al25 referred to 
a relationship between myocardial protein gene expression and decreased LV contractility in 
their   canine   model.                                                                                            
            A recent experimental study indicated that antioxidant vitamins such as beta-carotene, 
ascorbic acid and alpha-tocopherol reduced tissue oxidative stress in congestive heart failure and 
attenuated the associated cardiac dysfunction in a rabbit model. In addition, they also attenuated 
beta-receptor down regulation and sympathetic nerve terminal abnormalities. Therefore, it was 
emphasized that antioxidant therapy may be an efficacious method in treating human congestive 
heart   failure.26                                                                                     
            In a pig model of tachycardiomyopathy, Spinale et al27 observed a reduced myocardial 
blood flow reserve, particularly in the subendocardium and a decrease in endocardial/epicardial 
flow ratio. No significant morphological changes in the coronary vasculature were observed. 
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This suggests that the vascular structural changes were not responsible for the abnormalities in 
myocardial blood flow. The LV dysfunction and myocyte injury linked to tachycardiomyopathy 
are thought to be associated with reduced myocardial blood flow. Early recovery from 
supraventricular tachycardiomyopathy resulted in hypertrophy with normal myocardial blood 
flow   at   rest,   but   significantly   reduced   coronary   reserve.   However,   these   blood   flow 
abnormalities in tachycardiomyopathy have not sufficiently been evaluated in clinical series.
            In relation to the basic mechanisms of myocardial cell hypertrophy, Clemo et al28 tested 
the hypothesis that cellular hypertrophy in congestive heart failure modulates mechanosensitive 
channels. In canine models, swelling-activated inward rectifying cation current (I circ, swell) is 
persistently activated in tachycardiomyopathy. It is likely to be activated in multiple forms of 
cardiac hypertrophy and failure and may contribute to dysrythmias and altered contractile 
function. They suggested that I circ, swell may represent a novel target for therapeutic 
interventions.  
             A detailed summary of the functional and neurohumoral spectra of experimental 
tachycardiomyopathy is described by Fenelon et al.8  in their review.                                 
            In addition, recent studies elucidated that the progression of tachycardiomyopathy to 
heart failure facilitates ionic channel remodeling and it may contribute the generation of 
ventricular tachyarrhythmias. There have been many studies related to the ionic remodeling (K+ 
and Ca2+) of ventricular myocytes in experimental animals by rapid-pacing induced heart 
failure.29,30 A reduction in the density of transient potassium outward current(Ito) is the most 
consistent ionic current change in cardiac failure. The density of Ito is known to be variable 
regionally and transmurally, and it was reduced differentially in heart failure.31 Tomaselli GF et 
al32 indicated that the down-regulation of Ito may generate repolarization abnormalities and 
cause increased electrical instability of the failing heart. A recent study also pointed out the 
down-regulation of two components of the delayed rectifier potassium current (Ikr and Iks) in 
the pacing-induced  heart  failure  rabbit  model.33  It may prolong the action  potential at 
physiological cycle lengths and therefore contribute to arrhythmogenesis in heart failure. Han W, 
et al34 studied ionic remodeling of cardiac purkinje cells(PCs) isolated from control and pacing-
induced heart failure dogs. Their results showed that remodeling of K+ and Ca2+ currents occurs 
in PCs of tachycardia-induced heart failure dogs. Ik1 and Ito density were significantly smaller 
in congestive heart failure PCS and cause a reduction of the repolarization reserve. They 
concluded that the results may explain the ventricular arrhythmogenesis, particulary related to 
triggered activity in PCs, in patients with heart failure.                                    
Clinical   mechanisms                                                                          
            In clinical situations, tachycardiomyopathy is induced by various supraventricular and 
ventricular arrhythmias. Particularly in childhood, ectopic atrial tachycardia (EAT), a permanent 
form of junctional reciprocating tachycardia (PJRT) are most prevalently observed, which they 
are often incessant and refractory to antiarrhythmic drugs, and this commonly results in 
tachycardiomyopathy.35
            Human tachycardiomyopathy is considered to be similar to the mechanisms of most 
experimental models. A small number of studies suggest a hemodynamical changes in patients 
with tachycardiomyopathy.36 They are reduced LVEF, increased end-diastolic and end-systolic 
volumes, and increased end-diastolic and pulmonary artery pressures. Termination of the 
tachycardia lead to an improvement of clinical symptoms, an increase of EF and a marked 
decrease   of   end-systolic   volumes.   Concentric   LV   hypertrophy   following   recovery   from 
tachycardiomyopathy was not noted. Usually, the degree of LV dysfunction is not always related 
to the tachycardia duration or rate.1 Thease reasons are why the determination of the onset is 
quite difficult, since the patients without underlying diseases are asymptomatic until congestive 
heart failure occurs. On the other hand, patients with underlying heart disease are more likely to 
progress   toward   heart   failure.                                                                        
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            Paelinck B et al37 reported an evaluation method of myocardial contractile reserve in 
dilated cardiomyopathy with atrial fibrillation by using low-dose dobutamine echocardiography. 
They investigated using a wall motion score index, which was obtained by a summation of the 
individual wall motion scores of 16 segments of the left ventricle at baseline and after infusion 
of low-dose dobutamine as well as before and after cardioversion . The patients who showed a 
marked increase of LVEF at low-dose dobutamine and normalized EF at the follow-up were 
considered to have cardiomyopathy. These patient's wall motion score index had significantly 
improved, both at low-dose dobutamine and at the follow-up. On the contrary, no or low 
responders to dobutamine and wall motion score index were diagnosed as having dilated 
cardiomyopathy. It was suggested that low-dose dobutamine echocardiography predicts the 
improvement in LVEF after restoration of the sinus rhythm and is thus available in the 
identification   of   tachycardiomyopathy.                                                            
            Other factors related to LV function; age, underlying heart disease, drugs, irregurality of 
ventricular rhythm, short atrioventricular interval of less than 100ms are emphasized, yet remain 
to   be   determined.8                                                                               
             Regarding the mechanism of functional mitral regurgitation in tachycardiomyopathy, 
Timek TA et al38 studied the valvular and ventricular 3D geometric perturbations associated 
with MR in an ovine model of tachycardia-induced cardiomyopathy. According to the findings, 
the result of mitral annular dilatation and separation of the leaflet hinge points are the primary 
cause, which then led to incomplete leaflet coaptation and valve incompetence. Altered 
subvalvular leaflet tethering did not appear to play a major role in the pathogenesis of MR. 
Clinical   Diagnosis                                                                    
            A definite diagnosis of tachycardiomyopathy is sometimes difficult. A correct diagnosis 
can only be made by a normalization or improvement of the impairment of LV function after 
control of the tachyarrhythmias. However, it is also a fact that tachyarrhythmia control does not 
always bring about the improvement of LV function in patients with tachycardiomyopathy, and 
may simply reflect the irreversible stage of tachycardiomyopathy and complicate the diagnosis. 
Thus, no specific methods are available to identify the presence of tachycardiomyopathy at 
present. Therefore, it is important to suspect the existence of this condition from its history and 
clinical   findings.                                                                                
            Fenelon et al8 proposed the following criteria for the diagnosis of tachycardiomyopathy; 
in patients presenting with; 1) dilatation of the heart or heart failure, 2) Chronic or very frequent 
cardiac arrhythmias, including incessant supraventricular tachycardia, atrial fibrillation or flutter 
and incessant ventricular tachycardia. They further pointed out that if chronic tachycardia 
continued more than 10-15% of the day, with an atrial rate of more than 150% of that predicted 
for  age,  tachycardiomyopathy ensues.                                                                      
Treatment
            The basic concept for the treatment of tachycardiomyopathy is in controling the heart 
rate. The appropriate heart rate is beneficial for patients with tachycardia-induced heart failure. 
The   usual   approaches   for   tachycardiomyopathy   are   by   both   pharmacological   and   non-
pharmacological   treatments.                                                            
             In pharmacological therapy, drug choice depends on the underlying arrhythmias. In 
supraventricular tachycardia, digitalis or a Ca2+ antagonist (verapamil) are the common drugs of 
choice. Hayano M, et al39 reported a successful treatment of ectopic atrial tachycardiomyopathy 
by digitalis and verapamil. After gaining control of the heart rate, the LV diastolic dimension 
and cardiothoracic ratio were improved. They emphasized that initial medical treatment is 
preferable in the absence of a clinical emergency.                                                                       
          Usually, class I anti-arrhythmic drugs have a negative inotropic effect and therefore, the 
clinical use of these drugs for tachycardiomyopathy should be carefully decided according to the 
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patient's background. The case presented   here also had ectopic atrial tachycardiamyopathy, 
which was successfully treated with pilsicainide. This drug is a class Ic drug with a strong 
sodium channel blocking action and has a relatively short half-life compared to other Ic agents. 
In addition, a single oral dose is often effective for terminating supraventricular arrhythmias. For 
these reasons we cautiously administrated a single oral dose of pilsicainide (25mg), and it 
eventually terminated the EAT. Sinus rhythm was maintained at a dose of 75 mg/day and 
dramatic improvement of cardiac function was observed. Thus, if for some reason, catheter 
ablation cannot be performed as the first-line of therapy, class Ic drugs, including pilsicainide are 
an available option for the treatment of EAT-induced cardiomyopathy, provided that the patient 
is   carefully   observed.                                                                    
         In   pediatric   cases,   EAT   or   PJRT   is   often   incessant   and   commonly   results   in 
tachycardiomyopathy.  Amiodarone is the only available drug for patients with impaired LV 
function and tachyarrhythmias.40 In pediatric cases, EAT or PJRT is often incessant and 
commonly results in tachycardiomyopathy. Chen R.P-C.41 reported a case of PJRT which was 
successfully treated with amiodarone during the neonatal period. After 6 weeks systolic function 
improved. Complete resolution of ventricular tachycardia-induced cardiomyopathy by oral 
amiodarone in a young boy has also been reported.42  Treatment with other class III drugs 
including dofetilide, sotalol, ibutilide or azimilide may be another option. These class III drugs 
prolong the action potential duration and may enhance the inward calcium reflux resulting in 
increased contractility and are a favorable choice for tachycardiomyopathy if adverse effects are 
avoided. However, medical treatment is not always effective and safe, besides, several available 
drugs are ineffective in such cases. Therefore, a non-pharmacological approach is the next 
choice   in   the   treatment.                                                                          
Non-pharmacological   approach                                                                          
Catheter   ablation                                                                                      
            Since the introduction of radiofrequency (RF) ablation, the treatment of tachyarrhythmias 
has been safely performed and favorable results have been obtained. Simultaneously, it has been 
proven that the cure or control of tachyarrhythmia could improve LV function and heart failure 
in patitents with tachycardiomyopathy. Targeted arrhythmias are wide ranging, including 
EAT43, PSVT or PJRT 44-47 atrial fibrillation/flutter3,48 frequent isolated premature ventricular 
extrasystole49, and ventricular tachycardia  50-53. In most of these reports, cardiac function 
improved or normalized after successful RF ablation. These facts lead us to believe that catheter 
ablation in patients with tachycardiomyopathy should be performed as the first-line therapy as 
soon   as   possible.                                                                                
            RF ablation can even be used successfully even in a cardiac transplant patient with atial 
tachycardia-induced   cardiomyopathy.54                                                                 
Surgical   therapy                                                                                            
            Similary, a surgical treatment is also effective for patients who received operations to 
cure the tachyarrhythmias. Giorgi LV et al 55 reported the surgical treatment of an 11 year-old-
girl with focal atrial tachycardia and congestive heart failure which resulted in the improvement 
of LV function. Cruz FES et al4 reported the experience of surgical treatment of PSVT induced 
cardiomyopathy in 8 of 17 patients. After an average follow-up of 21.6 months, EF increased 
from 36% to 59%, LVDd decreased from 56 mm to 49 mm. They acknowledged the significance 
of surgery in such patients. Rabbani et al56 reported a case of DCM with EAT which was treated 
surgiclly. The patient received surgical cryoablation and LV function was improved 1 month 
after the operation. If catheter ablation cannot be performed as the first-line therapy for some 
reason, surgical therapy is an available option for the treatment of tachycardiomyopathy.  
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Prognosis
             Generally, if tachyarrhythmias are properly treated, cardiac function will recover. In 
bacic study, the recovery of LV systolic function requires about 2 weeks from the termination of 
pacing. However, in clinical situations, this may be quite variable both spatially and temporally 
because the length of tachycardia and underlying heart diseases are different in each patient. 
Conclusion
             The diagnosis of tachycardia-induced cardiomyopathy is not always simple, but we 
should start therapy if the patient suffers from congestive heart failure with tachyarrhythmias. 
This is because LV dysfunction may be recover after adequate treatment and it is the only way to 
make a definite diagnosis of tachycardiomyopathy. 
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